ATHLONE, Ireland, July 06, 2016 (GLOBE NEWSWIRE) — Innocoll Holdings plc (Nasdaq:INNL) a global, specialty pharmaceutical and medical device company with late stage development programs targeting areas of significant unmet medical need, today announced that Anthony Zook, Chief Executive Officer of Innocoll Holdings plc, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference taking place on July 12-13, 2016 at Le Parker Meridian Hotel in New York, NY.
Innocoll is scheduled to present on Tuesday, July 12, 2016 at 11:45 a.m. ET. Investors and analysts that are attending may request a one-on-one meeting with the company via investor relations or the Cantor registration link.
About Innocoll Holdings plc
Innocoll is a global, commercial-stage specialty pharmaceutical and medical device company. The company’s late stage product candidate pipeline is focused on addressing a number of large unmet medical needs, including: XARACOLL for the treatment of postoperative pain; INL-002 (COGENZIA), a gentamicin-collagen topical matrix for the adjuvant treatment of diabetic foot infections; and INL-003 (CollaGUARD), a barrier for the prevention of post-surgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®.
This press release contains forward-looking statements, including statements relating to Innocoll’s expectations regarding the completion, timing and size of the proposed public offering, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “goal,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. There can be no assurance that Innocoll will be able to complete the proposed public offering on the anticipated terms, or at all. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 20-F for the year ended December 31, 2015, filed on March 17, 2016, and our other reports filed with the Securities and Exchange Commission.
Innocoll Holdings plc